The Toxicologist - Society of Toxicology

More documents

Recommendations

Info

KEY WORD INDEX Keyword Index (Continued) drug development ...... 1148, 1804, 1807, 1808, 1896 drug discovery ...................... 2519, 2678 Drug Disposition ............................ 1915 drug dose-response relationship ..... 1575 Drug hypersensitivity reactions ........... 7 Drug impurities .......................... 6, 1812 Drug induced liver injuries (DILI) ... 940 drug induced liver injury .................. 438 Drug induced liver injury (DILI) .... 409, 425, 427, 446, 878, 2511 drug interaction .............................. 1844 Drug metabolism .................... 534, 1097 Drug metabolizing enzymes ........... 615, 1855 drug metabolizing enzymes, transporters ..................................... 2266 Drug of abuse ................................. 1834 drug processing genes ...................... 449 Drug Products ................................ 2573 Drug residues ................................... 710 drug screening ...................... 1898, 2677 drug transporters ........ 1058, 1108, 1915 drug-drug interaction ..................... 2280 Drug-drug Interactions ..................... 381 drug-induced hepatotoxicity .... 431, 463 drug-induced liver injury ........ 138, 423, 428, 435, 934 Drug-induced Phospholipidosis ....... 137 drug-induced vascular injury ........ 2669, 2670, 2672, 2674 Drug-related adverse events ..... 549, 854 Drywall .......................................... 1214 Duodenum ........................................ 269 duox.................................................. 631 dyslipidemia ................................... 1115 dysrhythmia .................................... 2114 E2F/Rb/HDAC1/2............................ 406 E7 oncoprotein ................................. 406 EAAT1/GLAST ............................... 394 early age ........................................... 701 Early Safety ...................................... 784 Early safety profiling ............... 479, 855 Earthworms .................................... 2406 ECa233 ........................................... 1842 E-cadherin ...................................... 2659 ECC1 cell line ................................ 2355 ECG.............. 195, 562, 570, 1919, 2359 economic adulteration .................... 2415 economy ......................................... 2481 Ecotoxicity ................... 327, 1482, 2465 ecotoxicology ........ 16, 826, 2397, 2462, 2463, 2464, 2467 EDSP .................................... 2358, 2559 education ................... 1866, 1870, 1872, 1875, 1880 Education and Career Development .................................... 419 Education and Outreach ....... 1865, 1869 EEG ...................................... 1355, 1806 EFT-300 ......................................... 2556 EGCG ............................................... 212 EGFR ............................................... 776 Egypt .................................... 1216, 1218 eicosanoids ..................................... 1837 elastase ........................................... 1652 Elastomer ....................................... 1550 Electrocardiographic ........................ 558 electrophile ..................................... 1787 Electrophoresis ............................... 1374 Electroretinogram ............................ 520 electroretinography .......................... 793 elimination ..................................... 1460 Embryo implantation ..................... 1025 Embryo toxicity ............................. 2391 embryogenesis ................................ 1634 embryonic development .......... 410, 839, 1616, 2445 embryonic stem cell ......................... 979 embryonic stem cell differentiation ... 76 610 SOT 2011 ANNUAL MEETING embryonic stem cell test ....... 73, 75, 991 Embryonic stem cells ....... 77, 837, 1019 embryotoxicity ....................... 979, 1045 emerging science .............................. 883 Employment ................................... 1879 EMS ............................................... 1405 EMT ................................................. 953 encapsulation .................................. 1358 endocannabinoid ............................ 2611 endocannabinoids ........................... 2086 Endocrine ............... 18, 246, 2094, 2559 endocrine active agent ...................... 623 endocrine active substances ........... 2466 endocrine disrupter ................. 692, 1537 Endocrine disrupters ...................... 2373 endocrine disrupting (ED) activity ............................................ 2367 endocrine disruption ........ 67, 494, 1066, 2202, 2346, 2348, 2351, 2358 endocrine disruptor ..... 624, 2092, 2186, 2349, 2352, 2375, 2383, 2388, 2602, 2603, 2667 Endocrine disruptor screening ....... 2375 endocrine disruptors ...... 531, 730, 1016, 1017, 1047, 2344, 2362, 2429 endocrine mode of action ................. 622 Endocrine Disrupting Chemicals ... 2091 endocrine-disrupting chemicals (EDCs) ........................................... 2367 endogenous AHR ligand ...... 1839, 1845 Endometriosis ................................ 2355 endoplasmic reticulum (ER) stress ............................................... 1998 Endoplasmic Reticulum Stress ....... 252, 2030 Endorphins ..................................... 2377 endothelial ...................... 189, 262, 1493 endothelial cell ............. 212, 2180, 2633 Endothelial cell function ................ 2066 Endothelial Cells ............ 191, 455, 2250 endothelial dysfunction ............ 186, 581 Endothelial function ......................... 554 endothelial progenitor cell ............. 2058 endothelial progenitor cells ............ 1170 endothelin-1 ................................... 1076 Endothelium ..................................... 959 Endotoxins ....................................... 668 energetic ......................................... 1544 energy ............................................. 1535 energy metabolism ......................... 2315 energy policy .................................. 2589 engine emission .............................. 1413 engine emissions ............................ 1555 engineering ..................................... 1730 Entomopathogenic nematodes ....... 1250 ENU ............................................... 1406 environmental ................................ 2394 environmental cardiology .............. 1170 Environmental Contaminants ......... 1579 environmental effects ..................... 1489 environmental epigenetics ............... 102 environmental exposure ................. 1970 environmental health .............. 883, 1873 Environmental monitoring ............. 1246 Environmental oxidants ..................... 23 Environmental pollutants ............... 1567 Environmental predictors ............... 1567 Environmental Statistics .................. 714 environmental tobacco smoke ......... 186, 1253, 1254 environmental toxicants ................... 819 environmental toxicology .............. 1257 enzyme inhibition ........................... 2098 Enzyme replacement therapy ........... 791 Enzymes ......................................... 2381 eosinophil peroxidase ......................... 54 EPA ................................................. 2559 EPA standard .................................. 1223 epidemiological study ...................... 292 Epidemiology ........ 47, 48, 49, 50, 1198, 1207, 1258, 1946, 1956 EPIDERM ............................ 2535, 2560 Epidermal Growth Factor Receptor ......................................... 2345 epidermal model ............................... 322 epigenetic ............. 106, 813, 1771, 2520 epigenetic changes ........................... 108 epigenetic regulation .............. 949, 2666 epigenetic toxicity ............................ 123 Epigenetics ...... 5, 12, 42, 100, 103, 105, 109, 110, 814, 817, 883, 946, 947, 950, 1167, 1621, 1700, 2071, 2187 Epigenomics ............................. 12, 1720 epilepsy ................................ 2020, 2037 EpiOcular ......................................... 644 Episkin ........................................... 2535 Epithelial Lung Cells ....................... 983 epoxide ........................................... 1843 eQTL .................................................. 41 equine flesh .................................... 1211 ER binding affinity........................... 494 ER stress....... 37, 262, 1083, 2224, 2532 ErbB2 ............................................... 206 ErbB3 ............................................... 776 Erionite ........................................... 1267 ERK.......................................... 276, 404 ERK1/2 mediated inflammation .... 2329 ER-negative .................................... 2634 ER-negative breast cancer .............. 2635 ER-negative xenograft ................... 2635 ER-stress; MAPK............................. 307 Erythrophagocytosis ........................ 294 ESL ................................................. 1523 Essential oils .................................. 2236 essentiality ...................................... 2459 esterases ......................................... 2047 Estrogen ........ 19, 172, 624, 1023, 1043, 1064, 1272, 2344, 2364, 2365 Estrogen carcinogenesis ................... 227 estrogen mediated .......................... 2303 estrogen receptor ........... 144, 372, 1016, 1017, 1708 estrogen receptor activation ........... 2357 estrogen receptor beta .................... 2365 Estrogenic Activity ................. 860, 2429 Estrogens ...................................... 17, 21 estrus cycle ..................................... 1042 ETBE ...................................... 515, 1531 ethanol ......... 679, 707, 968, 1082, 1301, 1302, 2147, 2620 ethinylestradiol ................................. 113 EthoVision XT ................................. 780 Ethyl Glurcuronide ......................... 1819 Ethyl tert-butyl ether (ETBE) ........ 1490 ethylene bisdithiocarbamate ........... 2087 ethylene glycol poisoning ................ 758 Ethylenediamine dinitrate .............. 1420 europe ............................................. 1877 Everyday compounds ..................... 2351 Evidence Combination ..................... 729 evolution ........................................ 1729 ex vivo .............................................. 823 EXCELERITE ............................... 2228 Excipients ............................... 507, 1928 Excitatory amino acid .................... 1571 excretion ......................................... 1194 Exercise ............................................ 537 Exhaled breath ............................... 2301 Exhaled Breath Condensate pH ..... 1212 Exosomes ......................................... 680 experimental autoimmune encephalomyelitis .......................... 1507 Experimental Design ...................... 2306 export ............................................... 312 Exposome ............................... 42, 44, 46 Exposomics ........................................ 43 exposure ...... 51, 824, 1181, 1224, 1243, 1244, 1259, 1794 exposure assessment ................. 50, 700, 731, 1239, 1251, 1258, 1262, 1545, 2118, 2504 exposure at schools .......................... 498 exposure model .............................. 1266 exposure risk .................................. 1264 exposure science ................................ 52 exposure-based testing ................... 1522 expression profiling ....................... 1410 Extended one generation study ....... 664, 1030, 2615, 2616 Extractable and Leachable ............. 1315 extractable/leachable ...................... 1323 Extrapolation ...................... 2, 938, 2476 eye .................................................... 793 eye irritant ...................................... 1521 eye irritation ................. 996, 1553, 2545 F1 ..................................................... 663 F1-extended one generation study ............................................... 1560 Factor XI .......................................... 216 FAS................................................. 2215 FAS Facial anomalies in rats .......... 1640 FasL ................................................ 1657 Fasting .................................. 2499, 2586 fathead minnow .............................. 2368 fatty acids ....................................... 2531 fau .................................................. 1673 FceRI .............................................. 2218 FDA guidelines .............................. 1723 Fe-depleted ....................................... 769 Feed Refusal ................................... 2419 Feed restriction ............................... 1574 female ............................................. 1024 female puberty ............................... 1042 female reproduction ....................... 1061 Females/Gender Differences ............ 583 Fenvalerate ..................................... 1070 Ferritin .................................. 2003, 2497 ferroportin ........................................ 312 Fertility ....................... 1040, 1050, 1923 fetal ...................................... 1022, 1635 fetal basis of adult disease .... 1043, 2191 Fetal Growth .................................. 1645 fetal growth restriction ................... 2085 fetal liver ........................................ 2185 Fetal programming ............................. 15 fetal testis ....................................... 1611 fetal toxicity ................................... 2095 FFPE tissue .................................... 1590 Fiber depositin in the lung ............. 2292 fiber equivalent diameter ............... 2293 Fiber inhalability .................. 2292, 2293 fiber pleura toxicology ..................... 600 fiber separation ............................... 2293 Fibrinogen ........................................ 765 Fibroblast ......................................... 303 Fibroblast Cells .............................. 2341 Fibrogenic Mediators ..................... 1183 fibrosis................ 602, 1082, 1119, 2178 FICZ ..................................... 1132, 1845 FICZ, 6-formylindolo[3, 2-b] carbazole .............................. 1839, 1852 Fipronil ........................................... 1355 Fire causalities ............................... 1217 Fire Sleeve ..................................... 1247 First-Pass Elimination .................... 1817 fish.................... 1537, 2384, 2391, 2465 Fish advisory .................................. 1572 fish and amphibians ....................... 2466 fish consumption .................. 1256, 1572 fish consumption advisory ............. 1249 Fish model ...................................... 1777 Fish Testing .................................... 2467 Fisher 344 rat ................................... 245 Fishing survey ................................ 1572 flame retardant ..................... 2253, 2640 Flame Retardants ................... 869, 2379 flavonoids ......................................... 616
Keyword Index (Continued) flow cytometry ................ 331, 339, 650, 651, 748, 1143, 1144, 1412, 1431, 1445, 1608, 1910 flow-through diffusion cell .............. 634 Fluojade B ...................................... 2037 fluorescent zebrafish ...................... 1614 Fluoride .......................................... 2201 fluoxetine ....................................... 2398 FMO3 ............................................. 1088 Focal adhesion kinase .................... 1387 Follicle ....................... 1033, 1035, 1036 folliculogenesis .............................. 1072 Folpet ............................................. 2260 Food ................... 882, 1252, 2120, 2416 food additive .......................... 325, 2630 food additives ................................... 155 food allergy .............. 89, 96, 1139, 2080 Food animals .................................... 710 Food contaminant ............................. 627 food defense ......................... 2432, 2433 food deprivation ............................. 2185 food ingredient ............................... 2438 Food Ingredients ............................ 2440 Food Nutrition ................................ 2429 food safety ....... 1525, 1688, 2415, 2427, 2434 foodborne pathogens ...................... 2413 Formaldehyde ........... 1683, 1690, 1719, 1944, 1945, 1946, 1947, 1948, 1949, 2301, 2558, 2651 formaldehyde dehydrogenase .......... 798 Formulation .......................... 2050, 2442 FOXA1 ............................................. 371 FOXI1 ............................................ 1602 foxq1 .............................................. 1631 Fractional Exhaled Nitric Oxide .... 1212 Fragrance ........................................ 1034 free fatty acids ................................ 1301 free radicals .................. 685, 1296, 1512 frontal cortex .................................. 2146 fructose ........................................... 1086 Fry .................................................... 953 FSH ................................................ 2398 FT-ICR-MS .................................... 1291 Fuel ................................................ 2304 fullerene ............................... 1194, 2576 fullerenes ........................................ 2161 fumonisin ....................................... 1448 Fumonisins ..................................... 2425 function .......................................... 1729 functional assay .............................. 1142 functional measurements ............... 1912 Functional observational battery .... 1549 Functional Toxicogenomics ........... 2558 functionalization .................. 2076, 2165 Fundulus ....................... 318, 1776, 2546 Fundulus heteroclitus ..................... 2007 Fungi .............................................. 2399 furan ....................................... 972, 1417 future ................................................ 922 FXR ................................................ 1104 GABA ............................................ 2140 GADD45a .............................. 317, 1414 GAL4/UAS-enhancer trap ............. 1467 Galantamine ................................... 2034 galectin-3 .......................................... 457 gallstones ........................................ 1113 Gamma Imaging ............................... 552 Gap junction ................................... 2637 gas dosimetry ................................. 2290 gaseous anesthetic .......................... 1661 gasoline emissions ......................... 2610 Gastrointestinal .................... 1427, 2165 Gastrointestinal Toxicity .......... 542, 792 GC/MS ........................................... 1695 gemfibrozil ..................................... 1890 Gender difference ........................... 2254 gene drug disease relationships ...... 1737 gene environment interaction ........ 1773, 1985 gene expression ....................... 119, 124, 126, 131, 196, 255, 380, 381, 591, 813, 820, 993, 1096, 1157, 1177, 1383, 1415, 1457, 1470, 1503, 1594, 1598, 1639, 1853, 2059, 2091, 2110, 2145, 2183, 2239, 2371, 2524, 2597 gene expression profile .................. 1590 Gene expression profiling ..... 135, 2052, 2318 gene expression, gene regulation ..... 413 gene network .................................... 131 gene networks ................................ 2322 gene profiling ................................. 1011 gene regulation ........ 365, 369, 376, 378, 1135, 1429, 1847, 1851, 2534 Gene Signaling ............................... 2092 gene signature ................................ 1587 gene silencing ................................. 1153 gene therapy ..................................... 382 Gene transfection ........................... 2526 gene-environment ............................ 292 Generic drug ..................................... 805 Genes and Environment ................. 1769 genetic .............................................. 842 Genetic analysis ............................... 962 Genetic differences ............................ 63 genetic polymorphism .................... 1979 genetic polymorphisms .................. 1270 genetic regulation ............................. 374 genetic susceptibility .............. 550, 1392 Genetic Toxicity ............................... 273 Genetic toxicology ....................... 11, 32 Genetic Variability ........................... 142 Genetically Modified Bacteria ....... 2440 Genetics .......................................... 1367 geniposide ...................................... 1827 genistein ..................... 2010, 2311, 2361 genome duplication ........................ 1775 Genomic ........................................... 876 genomic marker ............................. 1561 genomics ............ 442, 1601, 1717, 2090 genotoxic ........................................ 1950 Genotoxic impurities ........................ 152 Genotoxicity .............. 59, 116, 119, 238, 279, 280, 281, 282, 283, 317, 322, 324, 327, 328, 330, 331, 332, 333, 340, 343, 918, 997, 1003, 1005, 1180, 1359, 1403, 1405, 1410, 1412, 1414, 1415, 1419, 1420, 1422, 1469, 1918, 2027, 2075, 2115, 2238, 2575 genotoxicity and genomics ............ 2652 genotoxin ........................................ 1429 Genotyping ..................................... 1369 gentoxicity ........................................ 318 germ cells ....................................... 1657 Gestation ........................................ 1031 gestation/lactation .................. 706, 2104 Gestational Exposure ..................... 1032 Gestational Membranes ................. 2563 GHS classification ........................... 645 GILZ ................................................ 200 Gini Coefficient.............................. 1815 ginseng ............................................. 968 Glia ........................................... 178, 180 Global Chemicals Management ..... 1310 Global Chemicals Policy ................ 1310 Global Health ......................... 831, 2589 glucocorticoid .......................... 200, 886 Glucosamine .................................. 1893 Glutamate ......... 1401, 1513, 2025, 2625 glutamate cysteine ligase ............... 1280 glutamate transporter ....................... 394 glutamine transporter ..................... 2131 Glutathione .............................. 258, 259, 425, 752, 1106, 1193, 1308, 1421, 1778, 1835, 2328, 2514, 2621 Glutathione conjugates ................... 2319 Glutathione S-Transferases .............. 388 glutathione-depletion ..................... 2327 glutathione-s-transferase ................ 1447 glycation end products ..................... 391 glyceraldehyde-3-phosphate dehydrogenase ................................ 1305 Glycogen ........................................ 1620 glycolytic rate ................................. 2528 Glycosylation ................................. 1084 Glyphosate ..................................... 2108 Glyphosate herbicides .......... 1073, 1356 Glyphosate-surfactant herbicides ... 2114 GMO foods .................................... 1732 GnRH ............................................. 2354 gold nanoparticles ..... 1051, 1479, 2059, 2074, 2174 Göttingen minipig .................. 559, 1623 GPER ............................................. 1634 G-protein coupled receptor (GPCR) .......................................... 2343 gpt assay ......................................... 1405 gpt delta transgenic rat ................... 1403 Graduate education ........................ 1876 Grant .............................................. 1768 green chemistry ............... 497, 908, 909, 910, 911, 912, 913 green engineering ............................. 909 Green Tea Polyphenols .................. 2204 GreenScreen HC ............................ 1414 Growth ........................................... 1067 growth faltering ................................ 832 GSH.................................................. 753 GSNO reductase ............................... 798 GST ................................................ 1982 GST polymorphisms ...................... 2112 GSTs ............................................... 1362 GT-094 ............................................. 220 guideline ........................................... 471 Guideline Studies ........................... 2107 guidelines ............................. 1256, 2467 Guinea Pig ............................ 2034, 2035 Gulf of Mexico ......................... 825, 826 Gum Guggul................................... 2234 GWAS ................................................ 43 gynecological ................................. 2374 H295R .................................. 2351, 2547 H2A histone ................................... 2205 H9C2, glucose, galactose ................. 973 H9c2s ............................................. 1908 Haber’s Rule .................................... 572 haematology ................................... 2230 hair ................................................. 1238 hairless guinea pig .......................... 2013 Halfnium Oxide ............................. 1477 Haloacetates ................................... 1099 Halogenated aromatic hydrocarbons .................................... 924 Haloperidol .................................... 1615 Hands-on .............................. 1867, 1868 Hanford Miniature Swine ................ 636 haplotype ........................................ 1360 harm reduction ............................... 2694 harmonization .......................... 418, 495 hazard assessment ............................ 497 hazard categorization ..................... 1519 Hazard characterization ................. 1945 hazard classification ....................... 1521 hazard identification ................. 903, 907 HCS ................................................ 1889 HCV ................................................. 447 HDAC .............................................. 690 HDAC inhibitors .............................. 948 HDAC6 .......................................... 1279 HDO ................................................. 556 health ................ 922, 923, 924, 925, 926 health and safety ............................ 1517 health effects .................................. 1223 health guidance value ..................... 1811 health guidance values ................... 2298 Health Monitoring Data ................. 1199 health risk assessment ............ 597, 2292 hearing loss ...................................... 160 heart .... 203, 213, 442, 1647, 2008, 2359 Heart failure ..................... 196, 208, 214 Heart rate .................... 1166, 1487, 1645 Heart Rate Variability....................... 596 Heart Regeneration .................. 197, 198 heart slices ...................................... 1907 Heat Shock Protein ................ 395, 1750 heat stability ................................... 2431 Heatox .............................................. 882 heavy metal ...................................... 295 Heavy metals ........................ 1223, 1605 hedgehog signaling pathway .......... 1631 helicobacter pylori ......................... 2650 Hematologic toxicity ........................ 509 Hematological Effects .................... 1473 hematopoietic progenitor cells ....... 1168 hematopoietic stem cell ........ 1153, 1158 Hematopoietic stem cells ..... 1157, 1500 hematotoxicity ............ 1557, 1949, 2340 heme oxygenase-1 .......................... 2216 hemochromatosis ............................. 511 Hemodynamics ................................ 559 Hemoglobin .................................... 2320 Hemorrhagic shock/ Resuscitation .................................. 1648 hemostasis ...................................... 2047 hemostatic system .................. 433, 2022 HepaRG ................ 420, 935, 1903, 2516 HepaRG cells ................................. 1579 Heparin ............................................. 440 Hepatic and renal toxicity .............. 2222 Hepatic cells ................................... 1097 Hepatic fibrosis .............................. 2212 hepatic gene expression ................. 1584 hepatic steatosis ............................. 1117 Hepatic stellate cells ...................... 2212 hepatic toxicity ..................... 2522, 2523 Hepatic transporters ......................... 534 Hepatitis C ....................................... 690 Hepatocarcinogenesis .................... 2657 hepatocellular carcinoma ..... 1096, 1674 Hepatocyte ................... 429, 1098, 1173 hepatocytes .......... 311, 366, 1822, 1864, 2349, 2537, 2557 Hepatoprotective effect .................. 2224 Hepatotoxicants ................................ 532 hepatotoxicity .................. 139, 397, 420, 421, 424, 427, 428, 432, 434, 443, 444, 445, 448, 451, 454, 459, 805, 941, 995, 1089, 1119, 1173, 1269, 1577, 1590, 1678, 1705, 1710, 1735, 1834, 1899, 1905, 2418, 2539, 2540 hepatotoxins ..................................... 426 hepatoxicity .................................... 2561 hepcidin ............................................ 511 HepG2 .......................... 422, 1162, 1841 HepG2 cells .......................... 1667, 2531 Heptachlor .......................................... 98 Heptototoxicity ...................... 437, 1966 herbal .............................................. 2631 herbal supplement ................ 2374, 2439 herbicide diuron ............................... 547 Hexabromocyclododecane ............. 1252 hexachlorobenzene ............... 1358, 2685 hexahydro-1, 3, 5-trinitro-1, 3, 5-triazine ...................................... 736 Hexavalent chromium ..... 278, 915, 916, 917, 918, 920, 921, 2407 hexavalent chromium (CrVI) ......... 1597 HGF................................................ 1112 HIF-1 .............................................. 1652 high content .................................... 2540 High Content Analysis ..................... 420 high content cell-based imaging ....... 28, 31, 2511 High Content Image Analysis ......... 398, 2629 high content imaging .................... 29, 32 High Content Screening .......... 33, 1895, 1966 High Content Screening Assay ...... 1903 SOT 2011 ANNUAL MEETING 611 KEY WORD INDEX
Page 1 and 2:
The Toxicologist Supplement to Toxi
Page 3 and 4:
The Toxicologist Supplement to Toxi
Page 5 and 6:
1 BIODEGRADABLE MATERIALS FOR TISSU
Page 7 and 8:
that genetic toxicology data are ge
Page 9 and 10:
well-orchestrated lung inflammation
Page 11 and 12:
scribed in the literature. We have
Page 13 and 14:
years ago). We will illustrate how
Page 15 and 16:
involved in the biodegradation proc
Page 17 and 18:
stem cells but rather a treatment i
Page 19 and 20:
additional compound showed agreemen
Page 21 and 22:
82 COMPARISON OF 3H-THYMIDINE INCOR
Page 23 and 24:
irritants. While in practice these
Page 25 and 26:
alleles are especially vulnerable t
Page 27 and 28:
109 CD4+ T CELL INTRINSIC TNF RECEP
Page 29 and 30:
118 TO STUDY THE SIGNAL TRANSDUCTIO
Page 31 and 32:
PAHs, such as dioxins, are prevalen
Page 33 and 34:
containing substituents and/or hydr
Page 35 and 36:
146 COMPUTATIONAL MODELING FOR QT P
Page 37 and 38:
suggest that the combination of too
Page 39 and 40:
164 TRANSLOCATOR PROTEIN (18 KDA) (
Page 41 and 42:
function as a metal binding protein
Page 43 and 44:
laboratory has demonstrated that NR
Page 45 and 46:
known. The aim of this study was to
Page 47 and 48:
from 5 to 28 days in duration) in e
Page 49 and 50:
positive cells, caspase-3 activatio
Page 51 and 52:
creased level in the 46 kDa preproe
Page 53 and 54:
invasiveness at concentrations repr
Page 55 and 56:
thracene (DMBA,50 μg in acetone, a
Page 57 and 58:
247 CO-CARCINOGENESIS OF N, N- DIET
Page 59 and 60:
sponds to the endosomal dsRNA that
Page 61 and 62:
ODD in both WT (maximum 177% of con
Page 63 and 64:
Lastly, using p53siRNA cells, p53 w
Page 65 and 66:
its receptor Mpl to exert its funct
Page 67 and 68:
294 LOW LEVEL OF LEAD CAN INDUCE PH
Page 69 and 70:
lunar surface presented potential h
Page 71 and 72:
lar about cellular export mechanism
Page 73 and 74:
DNA in the kidney medulla, grandula
Page 75 and 76:
5.00 and 7.50 mg/kg/day by oral gav
Page 77 and 78:
events and carcinogenesis. Here we
Page 79 and 80:
tinization of cells of the hair fol
Page 81 and 82:
358 CHARACTERIZATION OF GENOME-WIDE
Page 83 and 84:
RNAi were also performed to identif
Page 85 and 86:
376 A FUNCTIONAL CROSSTALK BETWEEN
Page 87 and 88:
UGT1A gene induction, while this re
Page 89 and 90:
tivity, specifically peroxisome pro
Page 91 and 92:
and cytotoxic effects; however, its
Page 93 and 94:
histone deacetylase that is necessa
Page 95 and 96:
ment. Paradoxically, buthionine sul
Page 97 and 98:
drug leflunomide and its major (A77
Page 99 and 100:
442 GENE EXPRESSION AND MORPHOLOGIC
Page 101 and 102:
451 INHIBITION OF THE MITOCHONDRIAL
Page 103 and 104:
460 SULFORAPHANE PREVENTS ACETAMINO
Page 105 and 106:
drophilic/lipophilic balance. Other
Page 107 and 108:
pharmacokinetic and toxicological p
Page 109 and 110:
489 USE OF ‘OMICS DATA TO IMPROVE
Page 111 and 112:
498 APPLICATION OF AGE-SPECIFIC ADJ
Page 113 and 114:
507 A DOSE VOLUME TOLERABILITY STUD
Page 115 and 116:
involved the use of an acute inflam
Page 117 and 118:
sorption in the gastrointestinal (G
Page 119 and 120:
(ABC) transporters actively transpo
Page 121 and 122:
545 BEHAVIORAL EFFECTS OF REPIN IN
Page 123 and 124:
a blood pressure phenotype that res
Page 125 and 126:
and inhalation exposure system that
Page 127 and 128:
and lethality associated with these
Page 129 and 130:
position, on vascular reactivity an
Page 131 and 132:
therefore more accurate and reprodu
Page 133 and 134:
commercial chrysotile product that
Page 135 and 136:
elative to their controls. ST-depre
Page 137 and 138:
ats. The majority of the studies fo
Page 139 and 140:
in the China Jintan Child Cohort St
Page 141 and 142:
corneum thickness, cellular epiderm
Page 143 and 144:
645 EVALUATION OF THE IN VITRO EPIS
Page 145 and 146:
654 TCDD ADSORBED ONTO NATURAL AND
Page 147 and 148:
tion revealed no test article-relat
Page 149 and 150:
671 INFLAMMATION AND TISSUE DAMAGE
Page 151 and 152:
model, ethanol was found to inhibit
Page 153 and 154:
689 ENHANCED SUPPRESSIVE FUNCTION O
Page 155 and 156:
NAC + LPS yielded different levels
Page 157 and 158:
707 LIFE-STAGE PBPK MODELS FOR MULT
Page 159 and 160:
downstream of the apical endpoint o
Page 161 and 162:
726 UPDATED ALUMINUM PHARMACOKINETI
Page 163 and 164:
global parameter sensitivity analys
Page 165 and 166:
and renal inflammation induced by 2
Page 167 and 168:
754 PLASMA, URINE, AND TISSUE CONCE
Page 169 and 170:
cently characterized transporter OA
Page 171 and 172:
exposure system was developed from
Page 173 and 174:
lood cell mass and decrease in urin
Page 175 and 176:
practical alternatives to MC in non
Page 177 and 178:
imals dosed with 167 mg/kg THU alon
Page 179 and 180:
and organ weights, clinical signs a
Page 181 and 182:
yet is induced in most bladder and
Page 183 and 184:
830 RISK ASSESSMENT OF THE SPILL: C
Page 185 and 186:
knowledgebase creation. Results are
Page 187 and 188:
852 UNDERSTANDING STRUCTURAL AND PH
Page 189 and 190:
for integrating epidemiology and an
Page 191 and 192:
motor activity, including age of th
Page 193 and 194:
y partial purification of urine (fr
Page 195 and 196:
pacity for self-renewal and may dif
Page 197 and 198:
sue. The depth of our analysis led
Page 199 and 200:
910 IMPLEMENTING CALIFORNIA’S GRE
Page 201 and 202:
concentrations in six tissues and b
Page 203 and 204:
934 THE FDA’S LIVER TOXICITY KNOW
Page 205 and 206:
943 GENOME-WIDE DNA METHYLATION DIF
Page 207 and 208:
membrane localization and subsequen
Page 209 and 210:
trols, respectively. Subtoxic and t
Page 211 and 212:
survival using both smoking regimes
Page 213 and 214:
as non-, weak, moderate, or strong
Page 215 and 216:
988 NNK-INDUCED CYTOKINE ALTERATION
Page 217 and 218:
group (one-way ANOVA, p90 % viabili
Page 219 and 220:
ered as an organ involved in xenobi
Page 221 and 222:
Transport of CPZ across the Caco-2
Page 223 and 224:
estrous cycle and sexual behavior d
Page 225 and 226:
mRNA expression levels. Collectivel
Page 227 and 228:
1043 THE EFFECTS OF ENDOCRINE DISRU
Page 229 and 230:
1052 MONO-2-ETHYLHEXYL PHTHALATE IN
Page 231 and 232:
Results: MC was variable within and
Page 233 and 234:
UtSMCs. Phosphorylation of FoxO1 wa
Page 235 and 236:
nonpregnant and pregnant diabetic m
Page 237 and 238:
1089 PFOA-INDUCED LIVER EFFECTS IN
Page 239 and 240:
events in the liver. AZD9056 was ev
Page 241 and 242:
The peppermint oil caused a concent
Page 243 and 244:
OA did not affect food consumption.
Page 245 and 246:
1126 PERSISTENT DEVELOPMENTAL ARYLH
Page 247 and 248:
1135 BACH2 BINDING TO Prdm1 AS A ME
Page 249 and 250:
The purpose of this project was to
Page 251 and 252:
one marrow. Since Chk1 is an attrac
Page 253 and 254:
1163 THE MRNA AND MIRNA PROFILE OF
Page 255 and 256:
have now compared the IC50 values b
Page 257 and 258:
1181 ELUCIDATION OF FACTORS DETERMI
Page 259 and 260:
enced by pre-exposure to cigarette
Page 261 and 262:
if abnormal PF was associated with
Page 263 and 264:
weight (P=0.016) and small for gest
Page 265 and 266:
portant cause of death, compared to
Page 267 and 268:
posure groups. However, the differe
Page 269 and 270:
Naphthalene is routinely analyzed i
Page 271 and 272:
1245 SEASONAL CHARACTERIZATION OF H
Page 273 and 274:
1255 URINARY T, T MUCONIC ACID LEVE
Page 275 and 276:
modating a reliable data evaluation
Page 277 and 278:
enzoquinone generate ROS and arylat
Page 279 and 280:
teins (e.g. C3, 4, and 5, APOB, VDB
Page 281 and 282:
1293 TRANSFORMING GROWTH FACTOR BET
Page 283 and 284:
mation was decreased to the same le
Page 285 and 286:
1312 EVALUATION OF THE SENSITIVITY
Page 287 and 288:
luted OFR and CRL. Culture media ex
Page 289 and 290:
urinary TCPy levels, blood and brai
Page 291 and 292:
activity. The dose-response curves
Page 293 and 294:
mice, each with 4 dose groups. One
Page 295 and 296:
exposure to both ATR and DACT has a
Page 297 and 298:
third tetratricopeptide repeats (TP
Page 299 and 300:
7d. 28d after TMT injury there was
Page 301 and 302:
subunits. Each cell type was treate
Page 303 and 304:
1394 COMPARATIVE EFFECTS OF METHYLM
Page 305 and 306:
1403 GENOTOXICITY AND PRE-NEOPLASTI
Page 307 and 308:
vated only in high-dose-treated ani
Page 309 and 310:
1421 DOSE-RESPONSE OF NAPHTHALENE-I
Page 311 and 312:
cisplatin; 1.2-, 1.9- and 2.9-fold
Page 313 and 314:
Day 11 and started to recover on Da
Page 315 and 316:
1448 DEVELOPMENT OF A METHOD FOR QU
Page 317 and 318:
1457 GLOBAL GENE PROFILING REVEALS
Page 319 and 320:
cluding mouse and human macrophage,
Page 321 and 322:
model of lung inflammation and host
Page 323 and 324:
1484 NANOTOXICOLOGY AND NANOHEALTH
Page 325 and 326:
throughput in vitro approach was us
Page 327 and 328:
1502 IMMUNOLOGICAL ASPECTS OF AN AN
Page 329 and 330:
(CIA) and the Streptococcal cell wa
Page 331 and 332:
sitizers were 100% concordant among
Page 333 and 334:
1530 MINIMAL RISK LEVELS FOR STYREN
Page 335 and 336:
ical groups in the field of regulat
Page 337 and 338:
vitro with this potentially insect-
Page 339 and 340:
their performance on toxicological
Page 341 and 342:
need for a better understanding of
Page 343 and 344:
1577 AN IN VITRO MODEL SYSTEM FOR A
Page 345 and 346:
gene expression post-transcriptiona
Page 347 and 348:
1595 GENE EXPRESSION PROFILE OF RAT
Page 349 and 350:
to confirm a hepatotoxic property o
Page 351 and 352:
1613 AN INVESTIGATION OF THE CLEARA
Page 353 and 354:
its nuclear translocation was reduc
Page 355 and 356:
were collected from TK animals at d
Page 357 and 358:
egulated targets were selected for
Page 359 and 360:
U/L after tetracycline. Minocycline
Page 361 and 362:
peri-pubertal FasL-/- mice show a d
Page 363 and 364:
showed similar levels of apoptosis
Page 365 and 366:
1676 TWO BIOMARKERS FOR EVALUATION
Page 367 and 368:
motifs selected. This system was ap
Page 369 and 370:
1693 VOC SERUM LEVELS IN THE GENERA
Page 371 and 372:
1702 DOES THE CLOCK MAKE THE POISON
Page 373 and 374:
those with high nickel content are
Page 375 and 376:
isk assessment. However, unique cha
Page 377 and 378:
model of APAP metabolism and glutat
Page 379 and 380:
logically & morphologically similar
Page 381 and 382:
posure, blood chemistry was analyze
Page 383 and 384:
elated to oxidative stress by measu
Page 385 and 386:
ostasis), but work is needed to tra
Page 387 and 388:
tokine products during carcinogenes
Page 389 and 390:
ways as chemical stressors and, the
Page 391 and 392:
toxicity of nanomaterials relates s
Page 393 and 394:
1815 MEASURING COMPOUND SELECTIVITY
Page 395 and 396:
1825 EFFECTS OF METABOLISM BY INTES
Page 397 and 398:
cyanoacetic acid increased 2-3 fold
Page 399 and 400:
1845 IS THE PROMISCUITY OF THE ARYL
Page 401 and 402:
crorarray analysis. RT-PCR results
Page 403 and 404:
are a family of phase-II biotransfo
Page 405 and 406:
ous labs. As a result of positive s
Page 407 and 408:
down the doses may produce more tox
Page 409 and 410:
spectively. Below 100 mg/l of gemfi
Page 411 and 412:
1900 GENERATION OF PRECISION CUT LI
Page 413 and 414:
iomarkers or observation of lesions
Page 415 and 416:
creased reticulocytes and lymphocyt
Page 417 and 418:
statistically significant interacti
Page 419 and 420:
monize sample preparation and analy
Page 421 and 422:
NPC and sinonasal cancer in neighbo
Page 423 and 424:
showed incidences of lung and nasal
Page 425 and 426:
utylbenzenes, exhibited most simila
Page 427 and 428:
1975 DIFFERENTIAL MODULATION OF CYP
Page 429 and 430:
organic As to MMA(V) and a lower ca
Page 431 and 432:
ole in invasion and metastasis of c
Page 433 and 434:
3T3-L1 cells to low-levels of arsen
Page 435 and 436:
2011 IDENTIFICATION OF A NOVEL VX M
Page 437 and 438:
This work was supported by Cooperat
Page 439 and 440:
2029 EFFICACY OF ENDOTRACHEAL ADMIN
Page 441 and 442:
Diazepam injections and its combina
Page 443 and 444:
2047 ESTERASE ACTIVITIES AND HEMOST
Page 445 and 446:
nanoparticle-induced toxicity progr
Page 447 and 448:
house, were iv infused into rats ov
Page 449 and 450:
een explored. This study investigat
Page 451 and 452:
croscopic analysis revealed that on
Page 453 and 454:
egg yolk collected from turtles inh
Page 455 and 456:
consistency of results in both expe
Page 457 and 458:
2111 CYTOCHROME P450 3A5 GENOTYPE I
Page 459 and 460:
esidues of organophosphates or thei
Page 461 and 462:
manganism. Recent work from our lab
Page 463 and 464:
Aβ1-40 in CSF and hippocampus in P
Page 465 and 466:
2147 CATALASE MANIPULATIONS MODIFY
Page 467 and 468:
ation based on real-world exposure
Page 469 and 470:
NPs. Aggregation of citrate-stabili
Page 471 and 472:
2175 THE ROLE OF SURFACE CHEMISTRY
Page 473 and 474:
seen rapid uptake in biological ima
Page 475 and 476:
effect on uterine weight or vaginal
Page 477 and 478:
dicating widespread exposure. While
Page 479 and 480:
components into the liver parenchym
Page 481 and 482:
2223 ISOLATION AND DETECTION OF RIC
Page 483 and 484:
stored (-20 celsius degree). The co
Page 485 and 486:
2241 DDA, A BIOMARKER FOR ENVIRONME
Page 487 and 488:
2249 INTERACTION BETWEEN DIETARY SE
Page 489 and 490:
2258 PHARMACOKINETICS, EXCRETION BA
Page 491 and 492:
2267 SENSITIVE AND SPECIFIC FLUORES
Page 493 and 494:
2276 METABOLISM AND DISPOSITION OF
Page 495 and 496:
ment of hypertension in companion a
Page 497 and 498:
for the propyl series can be used f
Page 499 and 500:
2304 IN VITRO EXPOSURE AND EVALUATI
Page 501 and 502:
2313 THE SYNERGISTIC EFFECT OF SODI
Page 503 and 504:
genes that play a crucial role in M
Page 505 and 506:
2330 THE ROLE OF TRANSFORMING GROWT
Page 507 and 508:
ined following up to 96 h continuou
Page 509 and 510:
effect doses obtained with the rat
Page 511 and 512:
diated transcriptional response of
Page 513 and 514:
docrine disruptor activities of EDC
Page 515 and 516:
individuals. Week 6 results were qu
Page 517 and 518:
functionality of photosystem II and
Page 519 and 520:
wild mice (Mus musculus) from areas
Page 521 and 522:
2406 TOXICITY AND BIOACCUMULATION O
Page 523 and 524:
Isocitric acid is the acid in the h
Page 525 and 526:
2425 EFFECTS OF FUMONISINS IN ETHAN
Page 527 and 528:
centration(μg/g) were: 5.1-95.3; 2
Page 529 and 530:
2445 AUTOPHAGY IN DEVELOPMENT: A LI
Page 531 and 532:
sures to inhaled Mn in dust. Nevert
Page 533 and 534:
2466 CRITICAL EVALUATION OF ANIMAL
Page 535 and 536:
elationships predict that resting r
Page 537 and 538:
2489 COMPARATIVE TOXICITY OF BIODIE
Page 539 and 540:
2497 TRANSCRIPTIONAL REGULATION OF
Page 541 and 542:
2506 TOXICOLOGICAL CONSIDERATIONS O
Page 543 and 544:
launched with the aim of developing
Page 545 and 546:
forms mRNA expression levels were a
Page 547 and 548:
2534 CUTANEOUS WOUND HEALING IN THE
Page 549 and 550:
wells (0, 1, 5, 10, 25, 50, 100, an
Page 551 and 552:
2553 AN ORGANOTYPIC MICROLIVER PLAT
Page 553 and 554:
serum-free media. At 24 hrs, the gr
Page 555 and 556:
2572 INCREASED ARSENIC BIOACCESSIBI
Page 557 and 558:
nology to develop improved methods.
Page 559 and 560:
tuna, swordfish, or mako shark (3.5
Page 561 and 562:
nificantly reduce circulating thyro
Page 563 and 564: grouped into 9 observation periods
Page 565 and 566: histopathological or biochemical ev
Page 567 and 568: exhibited a hyperactive phenotype,
Page 569 and 570: the search of effective drugs for e
Page 571 and 572: 2644 COVALENT BINDING OF 14 C 2-MET
Page 573 and 574: aries targeting all transcription f
Page 575 and 576: (p 9 weeks) and CSC phenotype acqui
Page 577 and 578: 2673 IMMUNE-MEDIATED VASCULAR INJUR
Page 579 and 580: for risk identification and charact
Page 581 and 582: to control toxicant delivery in tob
Page 583 and 584: Author Index (Continued) The numera
Page 611 and 612: Keyword Index (Continued) Arsenite
Page 613: Keyword Index (Continued) Covalent
Page 617 and 618: Keyword Index (Continued) innate im
Page 619 and 620: Keyword Index (Continued) nanoparti
Page 621 and 622: Keyword Index (Continued) preservat
Page 623 and 624: Keyword Index (Continued) Thrombocy
Page 625 and 626: Toxicological Sciences The Official
show all

The Toxicologist - Society of Toxicology

Create successful ePaper yourself

Delete template?

Save as template?